Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Former head of Operation Warp Speed loses board seat over sexual harassment claims

By Sean Whooley | March 24, 2021

 

GlaxoSmithKline’s board of directors announced today that it terminated Moncef Slaoui as the chair of the Galvani board of directors.

Slaoui, who served as the head of Operation Warp Speed — the Trump administration’s program to accelerate COVID-19 vaccine development — was terminated effective immediately, according to a news release from GSK, the majority shareholder of Galvani Bioelectronics.

Termination of Slaoui follows the receipt of a letter alleging against him sexual harassment and inappropriate conduct towards a GSK employee. The allegations refer to incidents that occurred several years ago when he was a GSK employee.

Once GSK received the letter with the allegations, its board immediately initiated an investigation, bringing in a law firm to conduct it. That investigation substantiated the allegations made against Slaoui and remains ongoing.

“Dr. Slaoui’s behaviours are wholly unacceptable,” GSK wrote in the release. “They represent an abuse of his leadership position, violate company policies, and are contrary to the strong values that define GSK’s culture. The company expects everyone at GSK to behave in accordance with its values, especially its leaders where its standards are the highest. Sexual harassment and any abuse of leadership position are strictly prohibited and will not be tolerated.”

Current Galvani board member and the SVP of development at GSK, Christopher Corsico, has been appointed as the new chair of the board of Galvani. GSK SVP of legal, R&D & global commercial franchises Amy Altshul was also appointed to the board.

“GSK’s leadership is firmly committed to building a safe and respectful environment for every employee,” GSK wrote. “The company has established policies and resources to manage issues related to workplace safety and conduct while protecting the privacy and wellbeing of its employees. Over the last few years, it has worked hard to prioritize and enhance efforts to ensure that all employees feel respected and included.”


Filed Under: Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, Galvani, GlaxoSmithKline, Operation Warp Speed
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50